Literature DB >> 10843723

CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes.

P Terheyden1, P Straten, E B Bröcker, E Kämpgen, J C Becker.   

Abstract

Professional APC, notably dendritic cells (DC), are necessary for stimulation and expansion of naive T cells. By means of murine models, the interaction between CD40 on DC and its ligand CD154 has been recognized as an important element for conditioning of DC to prime and expand CTL. We translated these findings into the human system, scrutinizing the ability of DC to initiate clonal expansion of single T cells. DC generated under completely autologous conditions from peripheral blood monocytes were cocultured at a rate of 0.3 cell/well with melanoma-infiltrating T cells; this procedure guaranteed that either a CD4+ or a CD8+ cell interacted with the DC, thus avoiding the contact of more than one T cell to the DC. In the absence of further stimulation, this cloning protocol yielded almost exclusively CD4+ T cell clones that predominantly exhibited a Th2 phenotype. However, cross-linking of CD40 on DC resulted in the induction of IFN-gamma-producing Th1 CD4+ T cell clones. In addition, CD40-activated DC were capable of expanding CD8+ CTL clones. The ratio of CD4 to CD8 T cell clones corresponded to the ratio present in the initial tumor-infiltrating lymphocyte preparation. The CTL clones efficiently lysed autologous tumor cells whereas autologous fibroblasts or MHC-mismatched melanoma cells were not killed. Our findings support the critical role of CD40/CD154 interactions for the induction of cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843723     DOI: 10.4049/jimmunol.164.12.6633

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

2.  Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.

Authors:  Rongxin Zhang; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

3.  Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Authors:  Stefanie Gross; Michael Erdmann; Ina Haendle; Steve Voland; Thomas Berger; Erwin Schultz; Erwin Strasser; Peter Dankerl; Rolf Janka; Stefan Schliep; Lucie Heinzerling; Karl Sotlar; Pierre Coulie; Gerold Schuler; Beatrice Schuler-Thurner
Journal:  JCI Insight       Date:  2017-04-20

4.  MicroRNA expression profiling provides novel insights into immune-related pathways involved in gastric cancer.

Authors:  Mário Rino Martins; Renata Santos Almeida; Norma Lucena-Silva; Cláudia Malheiros Coutinho-Camilo; Israel Torjal; Rogério Luiz Dos Santos; Cristiana Libardi Miranda-Furtado; Álvaro Fabrício Lopes Rios; Leuridan Cavalcante Torres; Maria Dirlei F S Begnami
Journal:  Med Oncol       Date:  2019-08-09       Impact factor: 3.064

5.  HLA-DR+ immature cells exhibit reduced antigen-presenting cell function but respond to CD40 stimulation.

Authors:  Alberto Pinzon-Charry; Tammy Maxwell; Sandro Prato; Colin Furnival; Chris Schmidt; José Alejandro López
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

Review 6.  [Immunmodulatory antibodies in the treatment of skin cancer].

Authors:  D Schrama; A Hauschild; J C Becker
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

7.  Spontaneous apoptosis of blood dendritic cells in patients with breast cancer.

Authors:  Alberto Pinzon-Charry; Tammy Maxwell; Michael A McGuckin; Chris Schmidt; Colin Furnival; J Alejandro López
Journal:  Breast Cancer Res       Date:  2005-12-16       Impact factor: 6.466

8.  Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Authors:  Sung Nam Park; Kyung Tae Noh; Young-Il Jeong; In Duk Jung; Hyun Kyu Kang; Gil Sun Cha; Su Jung Lee; Jong Keun Seo; Dae Hwan Kang; Tae-Ho Hwang; Eun Kyung Lee; Byungsuk Kwon; Yeong-Min Park
Journal:  Exp Mol Med       Date:  2013-02-08       Impact factor: 8.718

9.  T-cell modulatory properties of CD5 and its role in antitumor immune responses.

Authors:  Mouna Tabbekh; M'barka Mokrani-Hammani; Georges Bismuth; Fathia Mami-Chouaib
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction.

Authors:  Alberto Pinzon-Charry; Chris W Schmidt; José Alejandro López
Journal:  Breast Cancer Res       Date:  2006-02-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.